NASDAQ · Biotechnology

SAB Biotherapeutics, Inc. (SABS) Stock

$2.94 +1.56% NASDAQ: SABS Healthcare

Valuation

MetricValue
Price$2.94
Market Cap$267.04M
P/E Ratio0.83
P/B Ratio1.11
P/S Ratio0.00
EPS (TTM)$-0.79
52-Week High$5.15
52-Week Low$1.97
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-6.74%
ROA-5.36%
ROCE-31.71%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.02
Current Ratio9.18

Annual Financials (USD)

Metric20212022202320242025
Revenue$61.0M$24.0M$2.0M$1.0M$0
Operating Profit$-13.0M$-29.0M$-38.0M$-43.0M$-49.0M
Net Profit$-17.0M$-19.0M$-42.0M$-34.0M$13.0M
EPS$-6.30$-4.31$-7.64$-3.68$-0.79
Op Margin-22.0%-121.0%-1700.5%-3244.9%—

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$81.0M$51.0M$84.0M$44.0M$173.0M
Total Liabilities$43.0M$20.0M$27.0M$18.0M$21.0M
Cash$33.0M$15.0M$57.0M$9.0M$11.0M
Borrowings$9.0M$6.0M$6.0M$5.0M$6.0M

Latest News

SAB Biotherapeutics (SABS) and Breakthrough T1D Award Research Grant For SAB-142 Assessment Insider Monkey · Jul 15, 2026 Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes GlobeNewswire · Jul 7, 2026 Why Is H.C. Wainwright Bullish On SAB Biotherapeutics (SABS) With $10 Price Target? Insider Monkey · Jul 5, 2026 Barclays Assigns Overweight Rating to SAB Biotherapeutics Inc. (SABS) Insider Monkey · Jun 30, 2026 Barclays Initiates SAB Biotherapeutics at Overweight With $13 Price Target MT Newswires · Jun 24, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$2.0M$-23.0M$-25.0M$-34.0M$-45.0M
Investing Cash Flow$-22.0M$-4.0M$0$-12.0M$-123.0M
Financing Cash Flow$34.0M$-5.0M$60.0M$0$0
Net Cash Flow$27.0M$-24.0M$42.0M$-48.0M$2.0M
Free Cash Flow$-9.0M$-26.0M$-25.0M$-35.0M$-46.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-28.32
FCF Yield-26.81%
Quick Ratio9.22
Interest Coverage-310.26
Return 1Y42.52%
Return 3Y-58.25%
Return 5Y-96.35%

Ownership

Insiders Held0.84%
Institutions Held92.44%
Institutions Float Held93.22%
Institutional HolderSharesReport Date
Vivo Capital, LLC11,420,0002026-03-31
Caligan Partners, LP7,967,2072026-03-31
Perceptive Advisors Llc6,431,7432026-03-31
Commodore Capital Lp4,401,5002026-03-31
RA Capital Management, L.P.4,401,5002026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ANTXAN2 Therapeutics, Inc. $4.39 -6.20% -5.24 $158.11M 0.00%
BOLDBoundless Bio, Inc. $2.53 -1.94% -0.92 $56.86M 0.00%
EVAXEvaxion Biotech A/S $3.05 +0.66% -1.99 $19.27M 0.00%
GBIOGeneration Bio Co. $5.34 +0.00% -0.87 $35.98M 0.00%
ITRMIterum Therapeutics plc $0.03 -10.98% -0.06 $1.60M 0.00%

About SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc. is led by CEO Samuel J. Reich, employs 63 people, headquartered in US, publicly traded since 2021.

SAB Biotherapeutics, Inc. (SABS) stock trades at $2.94 with a market capitalization of $267.04M. The stock is valued at a price-to-earnings (P/E) ratio of 0.83, price-to-book of 1.11, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.97 and $5.15, and currently trades 42.9% below its 52-week high.

On profitability, SAB Biotherapeutics, Inc. generates a return on equity (ROE) of -6.74%, return on capital employed of -31.71%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1176.71 +0.61% JNJ Johnson & Johnson $261.15 +1.82% ABBV AbbVie Inc. $277.39 +1.82% MRK Merck & Company, Inc. Common Stock (new) $146.33 +2.77% UNH UnitedHealth Group Incorporated Common Stock (DE) $378.12 +1.93% NVS Novartis AG $143.26 +0.10% AZN AstraZeneca PLC $159.37 +0.37% TMO Thermo Fisher Scientific Inc $659.71 +1.19% AMGN Amgen Inc. $415.61 +2.01% GILD Gilead Sciences, Inc. $151.28 +2.84% ABT Abbott Laboratories $99.16 +0.68% NVO Novo Nordisk A/S $38.39 +0.54%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides